Afficher la notice abrégée

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

dc.rights.licenseopenen_US
dc.contributor.authorMARLIN, Romain
dc.contributor.authorDESJARDINS, Delphine
dc.contributor.authorCONTRERAS, Vanessa
dc.contributor.authorLINGAS, Guillaume
dc.contributor.authorSOLAS, Caroline
dc.contributor.authorROQUES, Pierre
dc.contributor.authorNANINCK, Thibaut
dc.contributor.authorPASCAL, Quentin
dc.contributor.authorBEHILLIL, Sylvie
dc.contributor.authorMAISONNASSE, Pauline
dc.contributor.authorLEMAITRE, Julien
dc.contributor.authorKAHLAOUI, Nidhal
dc.contributor.authorDELACHE, Benoit
dc.contributor.authorPIZZORNO, Andres
dc.contributor.authorNOUGAIREDE, Antoine
dc.contributor.authorLUDOT, Camille
dc.contributor.authorTERRIER, Olivier
dc.contributor.authorDEREUDDRE-BOSQUET, Nathalie
dc.contributor.authorRELOUZAT, Francis
dc.contributor.authorCHAPON, Catherine
dc.contributor.authorHO TSONG FANG, Raphael
dc.contributor.authorVAN DER WERF, Sylvie
dc.contributor.authorROSA CALATRAVA, Manuel
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorMALVY, Denis
dc.contributor.authorDE LAMBALLERIE, Xavier
dc.contributor.authorGUEDJ, Jeremie
dc.contributor.authorLE GRAND, Roger
dc.date.accessioned2022-10-28T11:22:11Z
dc.date.available2022-10-28T11:22:11Z
dc.date.issued2022-08-30
dc.identifier.issn2041-1723en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170139
dc.description.abstractEnThe COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have been largely tested in clinical trials but failed so far to bring clear evidence of clinical efficacy is favipiravir, a nucleoside analogue with large spectrum activity against several RNA viruses in vitro and in small animal models. Here, we evaluate the antiviral activity of favipiravir against Zika or SARS-CoV-2 virus in cynomolgus macaques. In both models, high doses of favipiravir are initiated before infection and viral kinetics are evaluated during 7 to 15 days after infection. Favipiravir leads to a statistically significant reduction in plasma Zika viral load compared to untreated animals. However, favipiravir has no effects on SARS-CoV-2 viral kinetics, and 4 treated animals have to be euthanized due to rapid clinical deterioration, suggesting a potential role of favipiravir in disease worsening in SARS-CoV-2 infected animals. To summarize, favipiravir has an antiviral activity against Zika virus but not against SARS-CoV-2 infection in the cynomolgus macaque model. Our results support the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection.
dc.description.sponsorshipInfrastructure nationale pour la modélisation des maladies infectieuses humainesen_US
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enAntiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41467-022-32565-wen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36042198en_US
dc.description.sponsorshipEuropeA global alliance for Zika virus control and preventionen_US
dc.description.sponsorshipEuropeEuropean Vaccine Research and Development Infrastructureen_US
bordeaux.journalNature Communicationsen_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation pour la Recherche Médicaleen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-03797958
hal.version1
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature%20Communications&rft.date=2022-08-30&rft.volume=13&rft.issue=1&rft.eissn=2041-1723&rft.issn=2041-1723&rft.au=MARLIN,%20Romain&DESJARDINS,%20Delphine&CONTRERAS,%20Vanessa&LINGAS,%20Guillaume&SOLAS,%20Caroline&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_NC_2022_Marlin.pdf
Taille:
1.537Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée